Linezolid for Drug-Resistant Tuberculosis

The development of a highly effective, oral, 6-month regimen for the treatment of multidrug-resistant tuberculosis, which previously took 18 to 24 months to cure, is one of the defining achievements of the tuberculosis research community in this century. The results of the Nix-TB study, which were published in the Journal in 2020,1 showed that the combination of two new drugs, bedaquiline and pretomanid, with a repurposed oxazolidinone antibiotic agent, linezolid, given for 6 to 9 months to patients with drug-resistant or complicated multidrug-resistant tuberculosis, resulted in a favorable outcome in 98 of 109 patients (90%) at 6 months after the . . .